Torrent Pharmaceuticals Limited vs Gland Pharma Limited
An objective side-by-side of TORNTPHARM and GLAND, both in Pharmaceuticals - Indian - Formulations: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: TORNTPHARM Jun 2026 · GLAND Mar 2026
At a glance
- Torrent Pharmaceuticals Limited is the larger company by market value, about 3.9 times the size of Gland Pharma Limited.
- On trailing earnings, Gland Pharma Limited trades at the lower P/E (47.2 against 87.7).
- Torrent Pharmaceuticals Limited earns the higher return on equity (25.7% against 9.9%).
- Over three years Torrent Pharmaceuticals Limited has grown profits faster (22% a year against 8%).
- Over the past year the share prices returned +40.7% (TORNTPHARM) and +45.8% (GLAND).
| Metric | Torrent Pharmaceuticals TORNTPHARM |
Gland Pharma GLAND |
|---|---|---|
| Size and price | ||
| Market cap | ₹189,043 Cr | ₹48,503 Cr |
| Share price | ₹4,970 | ₹2,940 |
| Valuation | ||
| P/E | 87.68 | 47.20 |
| P/B | 22.54 | 4.68 |
| EV/EBITDA | 39.31 | 29.94 |
| PEG | 3.99 | 5.90 |
| Dividend yield | 0.8% | 0.6% |
| Profitability | ||
| ROE | 25.7% | 9.9% |
| ROCE | 15.0% | 15.0% |
| Operating margin | 33.0% | 25.3% |
| Sales (TTM) | ₹15,723 Cr | ₹6,431 Cr |
| Net profit (TTM) | ₹2,156 Cr | ₹1,028 Cr |
| Growth | ||
| Latest quarter sales YoY | +54.8% | +22.3% |
| Latest quarter profit YoY | +3.3% | +96.7% |
| Sales CAGR 3Y | +13.0% | +21.0% |
| Profit CAGR 3Y | +22.0% | +8.0% |
| Sales CAGR 5Y | +12.0% | +13.0% |
| Profit CAGR 5Y | +12.0% | +1.0% |
| Financial strength | ||
| Debt/Equity | 1.79 | 0.03 |
| Interest cover | 8.94 | 36.26 |
| Ownership | ||
| Promoter holding | 60.8% | 51.8% |
| Promoter change (4 qtrs) | -7.53 pp | -0.06 pp |
| Price performance | ||
| Return 1M | -0.70% | +4.26% |
| Return 3M | +11.51% | +34.46% |
| Return 1Y | +40.73% | +45.76% |
| Return YTD | +29.09% | +70.74% |
| Technical condition | ||
| Technical score | 68 | 83 |
| RS rating (1-99) | 78.00 | 92.00 |
| % vs 200-DMA | +13.23% | +39.97% |
| RSI (14) | 53.46 | 57.29 |
| % from 52-week high | -5.33% | -3.35% |
